Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.60 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.60 |
| ▸ | MAOB | P27338 | 6/20 | 0.59 |
| ▸ | IDO1 | P14902 | 2/20 | 0.46 |
| ▸ | AGXT | P21549 | 2/20 | 0.46 |
| ▸ | MGMT | P16455 | 2/20 | 0.42 |
| ▸ | APP | P05067 | 1/20 | 0.42 |
| ▸ | ELOVL1 | Q9BW60 | 1/20 | 0.41 |
| ▸ | CXCR2 | P25025 | 1/20 | 0.41 |
| ▸ | CA12 | O43570 | 1/20 | 0.41 |
| ▸ | CA1 | P00915 | 1/20 | 0.41 |
| ▸ | CA2 | P00918 | 1/20 | 0.41 |
| ▸ | CA7 | P43166 | 1/20 | 0.41 |
| ▸ | CA9 | Q16790 | 1/20 | 0.41 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.41 |
| ▸ | MPO | P05164 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11274684 | 0.85 | MEN1 (0.58) | MEN1KMT2AKDM4EMAOBELOVL1 | |
| SCHEMBL25382254 | 0.83 | AGXT (0.46) | MEN1KMT2AKDM4EMAOBAGXT | |
| SCHEMBL18429631 | 0.83 | APP (0.59) | MEN1KMT2AKDM4EIDO1APP | |
| SCHEMBL5652119 | 0.83 | MAOB (0.47) | MEN1KMT2AKDM4EMAOBIDO1 | |
| SCHEMBL11182657 | 0.83 | NPC1 (0.47) | MEN1KMT2AKDM4EMAOBIDO1 | |
| SCHEMBL21503592 | 0.83 | MAOB (0.59) | MAOBIDO1AGXTAPPELOVL1 | |
| SCHEMBL224083 | 0.82 | MAOB (0.56) | MEN1KMT2AKDM4EMAOBIDO1 | |
| SCHEMBL29561621 | 0.82 | MAOB (0.56) | MEN1KMT2AKDM4EMAOBIDO1 | |
| SCHEMBL30354929 | 0.82 | MAOB (0.62) | KMT2AKDM4EMAOBIDO1MPO | |
| SCHEMBL5652023 | 0.82 | MAOB (0.62) | KMT2AKDM4EMAOBIDO1MPO |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1542970-B1 | PYRROLIDONE DERIVATIVES AS MAOB INHIBITORS | HOFFMANN LA ROCHE (CH) | 2010-06-30 | — | — | EP | disclosed |
| EP-1542969-B1 | PYRROLIDONE DERIVATIVES AS MAOB INHIBITORS | HOFFMANN LA ROCHE (CH) | 2010-03-03 | — | — | EP | disclosed |
| CN-100503562-C | Pyrrolidone derivatives as MAOB inhibitors | HOFFMANN LA ROCHE (CH) | 2009-06-24 | — | — | CN | disclosed |
| CN-100400509-C | Pyrrolidone derivatives as MAOB inhibitors | HOFFMANN LA ROCHE (CH) | 2008-07-09 | — | — | CN | disclosed |
| US-7235559-B1 | Therapeutic quinazoline derivatives | ASTRAZENECA AB (SE) | 2007-06-26 | — | — | US | disclosed |
| US-7151111-B2 | 4-pyrrolidino-phenyl-benzyl ether derivatives | HOFFMANN-LA ROCHE INC. (US) | 2006-12-19 | — | — | US | disclosed |
| US-7122562-B2 | 4-pyrrolidino-phenyl-benzyl ether derivatives | HOFFMANN-LA ROCHE INC. (US) | 2006-10-17 | — | — | US | disclosed |
| US-20060122235-A1 | Amine oxidase inhibitor; use in treating Alzheimer's disease; for example, (RS)-1-[6-(4-fluoro-benzyloxy)-pyridin-3-yl]-5-oxo-pyrrolidine-3-carboxylic acid methylamide | IDING HANS | 2006-06-08 | — | — | US | disclosed |
| US-7037935-B2 | 4-Pyrrolidino-phenyl-benzyl ether derivatives | HOFFMANN-LA ROCHE INC. (US) | 2006-05-02 | — | — | US | disclosed |
| CN-1681778-A | Pyrrolidone derivatives as MAOB inhibitors | HOFFMANN LA ROCHE (CH) | 2005-10-12 | — | — | CN | disclosed |
| CN-1681777-A | Pyrrolidone derivatives as MAOB inhibitors | HOFFMANN LA ROCHE (CH) | 2005-10-12 | — | — | CN | disclosed |
| EP-1542969-A1 | PYRROLIDONE DERIVATIVES AS MAOB INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2005-06-22 | — | — | EP | disclosed |
| EP-1542970-A1 | PYRROLIDONE DERIVATIVES AS MAOB INHIBITORS | F.HOFFMANN-LA ROCHE AG (CH) | 2005-06-22 | — | — | EP | disclosed |
| US-20040116707-A1 | 4-Pyrrolidino-phenyl-benzyl ether derivatives | HOFFMANN-LA ROCHE INC. | 2004-06-17 | — | — | US | disclosed |
| US-20040106650-A1 | 4-Pyrrolidino-phenyl-benzyl ether derivatives | HOFFMANN-LA ROCHE INC. | 2004-06-03 | — | — | US | disclosed |
| WO-2004026825-A1 | PYRROLIDONE DERIVATIVES AS MAOB INHIBITORS | F.HOFFMANN-LA ROCHE AG (CH) | 2004-04-01 | — | — | WO | disclosed |
| WO-2004026827-A1 | PYRROLIDONE DERIVATIVES AS MAOB INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2004-04-01 | — | — | WO | disclosed |
| EP-1218355-A1 | THERAPEUTIC QUINAZOLINE DERIVATIVES | AstraZeneca AB (SE) | 2002-07-03 | — | — | EP | disclosed |
| WO-2001021597-A1 | THERAPEUTIC QUINAZOLINE DERIVATIVES | ASTRAZENECA AB (SE) | 2001-03-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040106650-A1 | 4-Pyrrolidino-phenyl-benzyl ether derivatives | MAOB, MAOA, COMT | MEN1 4505/4885KMT2A 1205/4885KDM4E 31/4885 |
| US-20060122235-A1 | Amine oxidase inhibitor; use in treating Alzheimer's disease; for example, (RS)-1-[6-(4-fluoro-benzyloxy)-pyridin-3-yl]-5-oxo-pyrrolidine-3-carboxylic acid methylamide | MAOA, MAOB, PNPO | MEN1 3745/4885KMT2A 606/4885KDM4E 176/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.